New hope for kids with tough cancers: First-of-its-Kind cell therapy trial

NCT ID NCT06612645

Summary

This early-stage study is testing a new type of personalized immune cell therapy called CMD03 in children and young adults whose solid tumors have come back or haven't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and infuse them back. The main goals are to see if this treatment is safe and to look for early signs that it can help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • King Chulalongkorn Memorial Hospital

    RECRUITING

    Bangkok, Pathumwan, 10330, Thailand

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.